Skip to content

Study · Systematic review · 2026

4 results

The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.

Chuang SM, Liu SC, Chien KL, Lin CJ, Tsai MC, Shih HM

Diabetes, obesity & metabolism31 May 2026Cited by 1 (Europe PMC)

PMID42219271 (opens in a new tab)PMCIDPMC13341365 (opens in a new tab)DOI10.1111/dom.70915 (opens in a new tab)PepBankPUB-42219271
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, injectable semaglutide, with efpeglenatide and albiglutide, showed the most favourable comparative MACE profiles in the network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, injectable semaglutide was among the drugs with the best results for major heart and blood vessel events.

    Peptide
    Semaglutide
    Outcome
    DecreaseMACE, agent-level network meta-analysis estimate
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · injectableAs given in this study (human).

    Source sentences

    Summary
    For MACE, efpeglenatide, albiglutide and injectable semaglutide showed the most favourable comparative profiles.
    3 context sentences
    Summary · context
    Pairwise meta-analyses and a frequentist random-effects NMA were performed for all-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), non-fatal myocardial infarction (MI) and non-fatal stroke.
    Summary · context
    PubMed, Cochrane Library and Scopus were searched through December 2025 for randomized controlled trials evaluating GLP-1-based therapies in adults with T2DM and reporting time-to-event cardiovascular outcomes.
    Summary · context
    Fifteen trials involving 97,173 participants were included.

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1-based therapies (a class that includes semaglutide) significantly reduced all-cause mortality versus placebo in pairwise analyses.

    In plain wordsIn adults with type 2 diabetes, GLP-1-based drugs as a group lowered deaths from any cause compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause mortality (pooled GLP-1-based therapies)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular

    Source sentences

    Summary
    In pairwise placebo-controlled analyses, GLP-1-based therapies significantly reduced all-cause mortality, cardiovascular mortality and MACE.
    2 context sentences
    Summary · context
    PubMed, Cochrane Library and Scopus were searched through December 2025 for randomized controlled trials evaluating GLP-1-based therapies in adults with T2DM and reporting time-to-event cardiovascular outcomes.
    Summary · context
    Fifteen trials involving 97,173 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1-based therapies (a class that includes semaglutide) significantly reduced cardiovascular mortality versus placebo in pairwise analyses.

    In plain wordsIn adults with type 2 diabetes, GLP-1-based drugs as a group lowered deaths from heart and blood vessel causes compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular mortality (pooled GLP-1-based therapies)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular

    Source sentences

    Summary
    In pairwise placebo-controlled analyses, GLP-1-based therapies significantly reduced all-cause mortality, cardiovascular mortality and MACE.
    2 context sentences
    Summary · context
    PubMed, Cochrane Library and Scopus were searched through December 2025 for randomized controlled trials evaluating GLP-1-based therapies in adults with T2DM and reporting time-to-event cardiovascular outcomes.
    Summary · context
    Fifteen trials involving 97,173 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1-based therapies (a class that includes semaglutide) significantly reduced major adverse cardiovascular events versus placebo in pairwise analyses.

    In plain wordsIn adults with type 2 diabetes, GLP-1-based drugs as a group lowered major heart and blood vessel events compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseMACE (pooled GLP-1-based therapies)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    In pairwise placebo-controlled analyses, GLP-1-based therapies significantly reduced all-cause mortality, cardiovascular mortality and MACE.
    2 context sentences
    Summary · context
    PubMed, Cochrane Library and Scopus were searched through December 2025 for randomized controlled trials evaluating GLP-1-based therapies in adults with T2DM and reporting time-to-event cardiovascular outcomes.
    Summary · context
    Fifteen trials involving 97,173 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    27 Oct 2026, 16:32 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    11 Oct 2026, 00:04 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.